Bioventures Investors

Bioventures Investors is a venture capital firm dedicated to investing in emerging and growth-stage medical technology companies. The firm focuses on identifying and supporting innovations that enhance healthcare outcomes, particularly in the fields of biotechnology, medical devices, diagnostics, digital health, and healthcare services. Their investment strategy emphasizes technologies that offer meaningful benefits to patients, healthcare providers, and payers, address rising healthcare costs, and are attractive to potential acquirers.

Founded in 1998, Bioventures Investors has a team with extensive experience in the MedTech sector. They have completed 28 MedTech transactions in the last decade and successfully exited 20 of these deals to date. The firm's MedTech-focused returns have an exceptional return profile. Their investment approach is to capture MedTech investment opportunities that contain radical innovation and enable paradigm shifts. They actively collaborate with portfolio companies, providing capital, guidance, and advice to foster growth and value creation.

Bioventures Investors is headquartered in Wellesley Hills, Massachusetts, a region known for its concentration of life science companies and research institutions. This location provides the firm with significant opportunities to access deal flow and talent in the region. The firm's founders, Peter Feinstein and Marc Goldberg, have worked closely on various healthcare enterprises since 1984, bringing a wealth of experience to their investment decisions. Their focus is on advancing the growth of MedTech by partnering with innovators who are changing the practice of medicine, investing in companies that are developing today's leading-edge biomedical technologies to improve health outcomes and reduce the cost of care.